MannKind quarterly sales climb a quarter as Furoscix upgrade and children's Afrezza gain traction
The inhaled-drug specialist posted $101.9m in third-quarter revenue, while a new Rose Pharma licence and early nintedanib data widen its inhaled pipeline.
MannKind said total revenue for the third quarter of 2026 reached $101.9m, an increase of 24% on the company's own headline measure. Of that, $45.0m came from commercial product sales, with the remainder arising outside that line. The breakdown of the non-product portion was not included in the information available.
The commercial story centres on Furoscix ReadyFlow, an FDA-approved presentation that began shipping in mid-September. By late October it made up roughly 75% of all Furoscix shipments, a swift handover from the earlier format. The company also pointed to the launch of Afrezza for paediatric patients, which it said lifted new prescriptions. No prescription volumes or product-level sales figures were provided.
On the pipeline side, MannKind reported positive tolerability data from INFLO-1, a Phase 1b study of inhaled nintedanib (MNKD-201) in idiopathic pulmonary fibrosis. A global Phase 2 trial is now under way. The company also announced a licensing agreement with Rose Pharma covering an inhaled GLP-1 product. Financial terms and development timelines for that deal were not disclosed in the material reviewed, and regulatory plans for both programmes remain to be set out.
Why it matters
- A rapid switch to Furoscix ReadyFlow, about 75% of shipments within roughly six weeks of launch, shows how quickly a new presentation can displace its predecessor, with implications for supply planning and transition management.
- Product revenue of $45.0m was well under half of the $101.9m total, so the headline growth rate reflects more than commercial sales alone; the make-up of the rest was not specified.
- Inhaled nintedanib in IPF and the Rose Pharma inhaled GLP-1 licence broaden MannKind's delivery-platform portfolio, but without deal terms or regulatory timelines their commercial value cannot yet be assessed.
Company's press release (SEC filing): Mannkind Corp ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
